潜在脑死亡捐献者的器官维护

杨顺良; 谭建明

doi:10.3969/j.issn.1674-7445.2015.05.002

潜在脑死亡捐献者的器官维护

doi: 10.3969/j.issn.1674-7445.2015.05.002

杨顺良,
谭建明^,

350251福州, 南京军区福州总医院泌尿外科全军器官移植研究所(杨顺良、谭建明); 厦门大学医学院附属东方医院 (杨顺良、谭建明)

基金项目:

国家临床重点专科军队建设项目 [2013]147

福建省重大专项资助项目 2012YZ0001

详细信息

作者简介:
杨顺良, 主任医师, 教授, 硕士研究生导师。从事肾移植、器官捐献的基础与临床工作, 在泌尿外科和肾移植疑难危重患者的诊断与处理方面积累了较丰富的经验。现任南京军区福州总医院泌尿外科副主任, 厦门大学、福建中医药大学教授、硕士研究生导师。兼任中国研究型医院学会移植医学委员会委员、中华医学会泌尿外科学分会肾移植学组委员、中华医学会器官移植学分会移植感染学组委员、福建省泌尿外科学会委员、南京军区器官移植学会委员。兼任《中华细胞与干细胞杂志:电子版》和《国际移植与血液净化杂志》编委。入选南京军区"334"高层次科技人才培养工程领军人才培养对象。以第一完成人获福建省科技成果二等奖1项, 军队医疗成果二等奖1项和军队医疗成果三等奖2项

通讯作者:
谭建明, Email:tanjm156@xmu.edu.cn

中图分类号: R617
计量
- 文章访问数: 98
- HTML全文浏览量: 52
- PDF下载量: 16
- 被引次数: 0
出版历程
- 收稿日期: 2015-06-03
- 网络出版日期: 2021-04-29
- 刊出日期: 2015-09-01

摘要

摘要: 近5年我国的公民逝世后器官捐献工作逐步进入常态化, 供体器官功能维护面临的挑战越来越大。供体器官功能维护直接关系到捐献成功率和受体安全, 但目前尚缺少供体维护的循证医学指南。确定器官维护目标能最大限度保持待捐器官的功能与活力。维护器官重点是稳定血流动力学指标(维持合适的循环血量、心排血量和灌注压), 保护肺换气功能, 纠正尿崩症和凝血障碍, 保持合适体温。本文从器官维护目标、供体维护的主要内容、器官获取过程中的供体维护等方面, 就潜在脑死亡捐献者的器官维护研究进展作一综述。
- 器官捐献 /
- 公民逝世后器官捐献 /
- 脑死亡 /
- 器官维护

HTML全文

表 1 美国器官获取组织制定的供体维护目标

Table 1. Donor maintenance targets set by Organ Procurement Organization in USA

指标	维护目标
平均动脉压	60～110mmHg
中心静脉压	5～16cmH₂O
射血分数	≥0.50
血管升压类药物	≤1种和低剂量[多巴胺≤10μg/(kg·min)，肾上腺素≤1μg/(kg·min)或去甲肾上腺素≤0.2μg/ (kg·min)]
动脉血气分析	pH值7.3～7.5
氧合指数	≥300mmHg(吸入氧气分数100%，呼气末正压通气5cmH₂O下测定)
血钠	≤155mmol/L
血糖	≤10.0mmol/L
尿量	过去4h内，≥0.5ml/(kg·h)
注：10mmHg=1.33kPa；1cmH₂O=0.098kPa

下载: 导出CSV

参考文献(45)

[1]	Abt PL, Marsh CL, Dunn TB, et al. Challenges to research and innovation to optimize deceased donor organ quality and quantity[J]. Am J Transplant, 2013, 13(6):1400-1404. doi: 10.1111/ajt.12243
[2]	Dhanani S, Shemie SD. Advancing the science of organ donor management[J]. Crit Care, 2014, 18(6):612. doi: 10.1186/s13054-014-0612-z
[3]	Salim A, Martin M, Brown C, et al. Complications of brain death:frequency and impact on organ retrieval[J]. Am Surg, 2006, 72(5):377-381. https://www.ncbi.nlm.nih.gov/pubmed/16719188
[4]	Malinoski DJ, Patel MS, Daly MC, et al. The impact of meeting donor management goals on the number of organs transplanted per donor:results from the United Network for Organ Sharing Region 5 prospective donor management goals study[J]. Crit Care Med, 2012, 40(10):2773-2780. doi: 10.1097/CCM.0b013e31825b252a
[5]	Sally M, Malinoski D. Current research on organ donor management[J]. Anesthesiol Clin, 2013, 31(4):737-748. doi: 10.1016/j.anclin.2013.08.004
[6]	项和立, 薛武军, 田普训, 等.公民逝世后器官捐献供者的评估与维护[J].中华器官移植杂志, 2014, 35(7):392-395. http://www.docin.com/p-1104947575.html
[7]	Franklin GA, Santos AP, Smith JW, et al. Optimization of donor management goals yields increased organ use[J]. Am Surg, 2010, 76(6):587-594. https://www.ncbi.nlm.nih.gov/pubmed/20583513
[8]	Hagan ME, McClean D, Falcone CA, et al. Attaining specific donor management goals increases number of organs transplanted per donor:a quality improvement project[J]. Prog Transplant, 2009, 19(3):227-231. doi: 10.7182/prtr.19.3.wq3w28052k5q6334
[9]	Malinoski DJ, Daly MC, Patel MS, et al. Achieving donor management goals before deceased donor procurement is associated with more organs transplanted per donor[J]. J Trauma, 2011, 71(4):990-996. doi: 10.1097/TA.0b013e31822779e5
[10]	Hömme R, Neeser G. Organ donation[J]. Anaesthesist(德文), 2007, 56(12):1291-1303. doi: 10.1007/s00101-007-1284-8
[11]	Dupuis S, Amiel JA, Desgroseilliers M, et al. Corticosteroids in the management of brain-dead potential organ donors:a systematic review[J]. Br J Anaesth, 2014, 113(3):346-359. doi: 10.1093/bja/aeu154
[12]	Dictus C, Vienenkoetter B, Esmaeilzadeh M, et al. Critical care management of potential organ donors:our current standard[J]. Clin Transplant, 2009, 23(Suppl 21):2-9. https://www.ncbi.nlm.nih.gov/pubmed/19930309
[13]	Mutter TC, Ruth CA, Dart AB. Hydroxyethyl starch (HES) versus other fluid therapies:effects on kidney function[J].Cochrane Database Syst Rev, 2013, 7:CD007594. https://www.ncbi.nlm.nih.gov/pubmed/23881659/
[14]	Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care[J]. N Engl J Med, 2012, 367(20):1901-1911. doi: 10.1056/NEJMoa1209759
[15]	Cittanova ML, Mavré J, Riou B, et al. Long-term follow-up of transplanted kidneys according to plasma volume expander of kidney donors[J]. Intensive Care Med, 2001, 27(11):1830. doi: 10.1007/s00134-001-1110-8
[16]	Venkateswaran RV, Patchell VB, Wilson IC, et al. Early donor management increases the retrieval rate of lungs for transplantation[J].Ann Thorac Surg, 2008, 85(1):278-286. doi: 10.1016/j.athoracsur.2007.07.092
[17]	Wood KE, Coursin DB. Intensivists and organ donor management[J]. Curr Opin Anaesthesiol, 2007, 20(2):97-99. doi: 10.1097/ACO.0b013e3280895ac8
[18]	Ishimura T, Muramaki M, Kishikawa H, et al. The impact of donor factors on early graft function in kidney transplantation from donation after cardiac death[J]. Transplant Proc, 2014, 46(4):1064-1066. doi: 10.1016/j.transproceed.2013.11.070
[19]	Marinosci GZ, De Robertis E, De Benedictis G, et al. Dopamine use in intensive care:are we ready to turn it down?[J]. Transl Med UniSa, 2012, 4:90-94. https://www.ncbi.nlm.nih.gov/pubmed/23905068
[20]	Cicci JD, Reed BN, McNeely EB, et al. Acute decompensated heart failure:evolving literature and implications for future practice[J]. Pharmacotherapy, 2014, 34(4):373-388. doi: 10.1002/phar.1369
[21]	García Sáez D, Zych B, Sabashnikov A, et al. Evaluation of the organ care system in heart transplantation with an adverse donor/recipient profile[J]. Ann Thorac Surg, 2014, 98(6):2099-2106. doi: 10.1016/j.athoracsur.2014.06.098
[22]	Spindler RS, Schnuelle P, Nickels L, et al. N-octanoyl dopamine for donor treatment in a brain-death model of kidney and heart transplantation[J]. Transplantation, 2015, 99(5):935-941. doi: 10.1097/TP.0000000000000577
[23]	Fontana J, Yard B, Stamellou E, et al. Dopamine treatment of brain-dead Fisher rats improves renal histology but not early renal function in Lewis recipients after prolonged static cold storage[J]. Transplant Proc, 2014, 46(10):3319-3325. doi: 10.1016/j.transproceed.2014.04.020
[24]	Hanusch C, Hauser C, Geisler A, et al. Reduction of oedema formation after preconditioning with dopamine in an isolated rat lung model is mediated by adrenergic receptors[J]. Ann Transplant, 2011, 16(3):97-107. doi: 10.12659/AOT.882001
[25]	Hanusch C, Nowak K, Törlitz P, et al. Donor dopamine treatment limits pulmonary oedema and inflammation in lung allografts subjected to prolonged hypothermia[J]. Transplantation, 2008, 85(10):1449-1455. doi: 10.1097/TP.0b013e31816f220d
[26]	Rech TH, Moraes RB, Crispim D, et al. Management of the brain-dead organ donor:a systematic review and meta-analysis[J]. Transplantation, 2013, 95(7):966-974. doi: 10.1097/TP.0b013e318283298e
[27]	Von Ziegler F, Helbig S, Kreissl N, et al. Norepinephrine versus dopamine pretreatment of potential heart donors-impact on long-term outcome[J]. Ann Transplant, 2013, 18:320-326. doi: 10.12659/AOT.883960
[28]	Callahan DS, Neville A, Bricker S, et al. The effect of arginine vasopressin on organ donor procurement and lung function[J]. J Surg Res, 2014, 186(1):452-457. doi: 10.1016/j.jss.2013.09.028
[29]	Stoica SC, Satchithananda DK, White PA, et al. Noradrenaline use in the human donor and relationship with load-independent right ventricular contractility[J]. Transplantation, 2004, 78(8):1193-1197. doi: 10.1097/01.TP.0000137792.74940.4F
[30]	Di Giantomasso D, Morimatsu H, Bellomo R, et al. Effect of low-dose vasopressin infusion on vital organ blood flow in the conscious normal and septic sheep[J]. Anaesth Intensive Care, 2006, 34(4):427-433.
[31]	Salim A, Martin M, Brown C, et al. Using thyroid hormone in brain-dead donors to maximize the number of organs available for transplantation[J]. Clin Transplant, 2007, 21(3):405-409. doi: 10.1111/ctr.2007.21.issue-3
[32]	冼颖欣, 陈国栋.心脏死亡器官捐献供肾质量评估和改善方法的新进展[J].器官移植, 2013, 4(2):113-116. http://www.cnki.com.cn/Article/CJFDTOTAL-QGYZ201302013.htm Xian YX, Chen GD. New progress in assessment and improvement of graft quality in kidney transplantation from donation after cardiac death[J]. Organ Transplant, 2013, 4(2):113-116. http://www.cnki.com.cn/Article/CJFDTOTAL-QGYZ201302013.htm
[33]	Kotsch K, Ulrich F, Reutzel-Selke A, et al. Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation:a prospective randomized controlled trial[J]. Ann Surg, 2008, 248(6):1042-1050. doi: 10.1097/SLA.0b013e318190e70c
[34]	Hevesi ZG, Lopukhin SY, Angelini G, et al. Supportive care after brain death for the donor candidate[J]. Int Anesthesiol Clin, 2006, 44(3):21-34. doi: 10.1097/01.aia.0000210798.53007.4b
[35]	Kamiya M, Sato N, Nozaki A, et al. Renal effects of added low-dose dopamine in acute heart failure patients with diuretic resistance to natriuretic peptide[J]. J Cardiovasc Pharmacol, 2015, 65(3):282-288. doi: 10.1097/FJC.0000000000000193
[36]	Botha P, Rostron AJ, Fisher AJ, et al. Current strategies in donor selection and management[J]. Semin Thorac Cardiovasc Surg, 2008, 20(2):143-151. doi: 10.1053/j.semtcvs.2008.04.006
[37]	Ware LB, Landeck M, Koyama T, et al. A randomized trial of the effects of nebulized albuterol on pulmonary edema in brain-dead organ donors[J].Am J Transplant, 2014, 14(3):621-628. doi: 10.1111/ajt.12564
[38]	Angel LF, Levine DJ, Restrepo MI, et al. Impact of a lung transplantation donor-management protocol on lung donation and recipient outcomes[J]. Am J Respir Crit Care Med, 2006, 174(6):710-716. doi: 10.1164/rccm.200603-432OC
[39]	Mascia L, Pasero D, Slutsky AS, et al. Effect of a lung protective strategy for organ donors on eligibility and availability of lungs for transplantation:a randomized controlled trial[J]. JAMA, 2010, 304(23):2620-2627. doi: 10.1001/jama.2010.1796
[40]	Hanna K, Seder CW, Weinberger JB, et al. Airway pressure release ventilation and successful lung donation[J]. Arch Surg, 2011, 146(3):325-328. doi: 10.1001/archsurg.2011.35
[41]	Peris A, Bagatti S, Lo Pane P, et al. Opposition to organ donation:prevention is better than applying tactics[J]. Crit Care, 2014, 18(6):598. doi: 10.1186/s13054-014-0598-6
[42]	胡益民, 纪木火.精氨酸加压素的临床应用[J].实用医学杂志, 2011, 27(13):2475-2477. http://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ201113077.htm Hu YM, Ji MH. Clinical application of arginine vasopressin[J]. J Pract Med, 2011, 27(13):2475-2477. http://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ201113077.htm
[43]	Marshall GR, Mangus RS, Powelson JA, et al. Donor management parameters and organ yield:single center results[J]. J Surg Res, 2014, 191(1):208-213. doi: 10.1016/j.jss.2014.02.054
[44]	Shutter L. Pathophysiology of brain death:what does the brain do and what is lost in brain death?[J]. J Crit Care, 2014, 29(4):683-686. doi: 10.1016/j.jcrc.2014.04.016
[45]	Bernhardt AM, Reichenspurner H. High-risk donors:extending our criteria in times of organ shortage[J]. Curr Opin Organ Transplant, 2014, 19(5):494-499. doi: 10.1097/MOT.0000000000000118